vs
Amneal Pharmaceuticals, Inc.（AMRX）とRyman Hospitality Properties, Inc.（RHP）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amneal Pharmaceuticals, Inc.の直近四半期売上が大きい（$814.3M vs $737.8M、Ryman Hospitality Properties, Inc.の約1.1倍）。Ryman Hospitality Properties, Inc.の純利益率が高く（10.1% vs 4.3%、差は5.8%）。Ryman Hospitality Properties, Inc.の前年同期比売上増加率が高い（13.9% vs 11.5%）。Amneal Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$108.5M vs $58.5M）。過去8四半期でRyman Hospitality Properties, Inc.の売上複合成長率が高い（18.2% vs 11.1%）
アムニールファーマシューティカルズは米国の上場製薬企業で、後発医薬品と専門医薬品の開発・製造・流通を事業の柱としています。本社はニュージャージー州ブリッジウォーターに位置し、米国最大級の後発医薬品メーカーの1つです。
ライマン・ホスピタリティ・プロパティーズは、ホテル・リゾート・エンターテインメント・メディア事業を手がける企業で、テネシー州ナッシュビルに所在する国の歴史的ランドマーク「ライマン・オーディトリアム」に由来して社名が付けられた。1983年のWSM社買収を機に現在の事業基盤を構築、人気音楽公演ブランド「グランド・オール・オプリ」なども保有している。
AMRX vs RHP — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $814.3M | $737.8M |
| 純利益 | $35.1M | $74.5M |
| 粗利率 | 36.5% | 41.4% |
| 営業利益率 | 13.8% | 19.4% |
| 純利益率 | 4.3% | 10.1% |
| 売上前年比 | 11.5% | 13.9% |
| 純利益前年比 | 212.9% | 3.0% |
| EPS（希薄化後） | $0.10 | $1.12 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $814.3M | $737.8M | ||
| Q3 25 | $784.5M | $592.5M | ||
| Q2 25 | $724.5M | $659.5M | ||
| Q1 25 | $695.4M | $587.3M | ||
| Q4 24 | $730.5M | $647.6M | ||
| Q3 24 | $702.5M | $550.0M | ||
| Q2 24 | $701.8M | $613.3M | ||
| Q1 24 | $659.2M | $528.3M |
| Q4 25 | $35.1M | $74.5M | ||
| Q3 25 | $2.4M | $34.9M | ||
| Q2 25 | $22.4M | $71.8M | ||
| Q1 25 | $12.2M | $63.0M | ||
| Q4 24 | $-31.1M | $72.3M | ||
| Q3 24 | $-156.0K | $59.0M | ||
| Q2 24 | $6.0M | $100.8M | ||
| Q1 24 | $-91.6M | $42.8M |
| Q4 25 | 36.5% | 41.4% | ||
| Q3 25 | 34.9% | 40.9% | ||
| Q2 25 | 39.5% | 49.7% | ||
| Q1 25 | 36.8% | 44.4% | ||
| Q4 24 | 36.0% | 40.4% | ||
| Q3 24 | 38.4% | 43.1% | ||
| Q2 24 | 35.6% | 48.4% | ||
| Q1 24 | 36.1% | 41.5% |
| Q4 25 | 13.8% | 19.4% | ||
| Q3 25 | 9.0% | 15.0% | ||
| Q2 25 | 15.4% | 21.1% | ||
| Q1 25 | 14.4% | 19.8% | ||
| Q4 24 | 10.4% | 18.6% | ||
| Q3 24 | 12.6% | 19.3% | ||
| Q2 24 | 13.6% | 27.4% | ||
| Q1 24 | -1.6% | 18.2% |
| Q4 25 | 4.3% | 10.1% | ||
| Q3 25 | 0.3% | 5.9% | ||
| Q2 25 | 3.1% | 10.9% | ||
| Q1 25 | 1.8% | 10.7% | ||
| Q4 24 | -4.3% | 11.2% | ||
| Q3 24 | -0.0% | 10.7% | ||
| Q2 24 | 0.9% | 16.4% | ||
| Q1 24 | -13.9% | 8.1% |
| Q4 25 | $0.10 | $1.12 | ||
| Q3 25 | $0.01 | $0.53 | ||
| Q2 25 | $0.07 | $1.12 | ||
| Q1 25 | $0.04 | $1.00 | ||
| Q4 24 | $-0.10 | $1.12 | ||
| Q3 24 | $0.00 | $0.94 | ||
| Q2 24 | $0.02 | $1.65 | ||
| Q1 24 | $-0.30 | $0.67 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.0M | $471.4M |
| 総負債低いほど良い | $2.6B | — |
| 株主資本純資産 | $-70.8M | $750.2M |
| 総資産 | $3.7B | $6.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.0M | $471.4M | ||
| Q3 25 | $201.2M | $483.3M | ||
| Q2 25 | $71.5M | $420.6M | ||
| Q1 25 | $59.2M | $413.9M | ||
| Q4 24 | $110.6M | $477.7M | ||
| Q3 24 | $74.0M | $534.9M | ||
| Q2 24 | $43.8M | $498.4M | ||
| Q1 24 | $46.5M | $465.3M |
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
| Q4 25 | $-70.8M | $750.2M | ||
| Q3 25 | $-109.5M | $758.5M | ||
| Q2 25 | $-112.1M | $800.4M | ||
| Q1 25 | $-131.7M | $531.5M | ||
| Q4 24 | $-109.3M | $549.0M | ||
| Q3 24 | $-93.4M | $551.9M | ||
| Q2 24 | $-57.5M | $562.6M | ||
| Q1 24 | $-63.7M | $529.9M |
| Q4 25 | $3.7B | $6.2B | ||
| Q3 25 | $3.6B | $6.2B | ||
| Q2 25 | $3.4B | $6.1B | ||
| Q1 25 | $3.4B | $5.2B | ||
| Q4 24 | $3.5B | $5.2B | ||
| Q3 24 | $3.5B | $5.2B | ||
| Q2 24 | $3.5B | $5.1B | ||
| Q1 24 | $3.5B | $5.1B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $130.3M | $164.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $108.5M | $58.5M |
| FCFマージンFCF / 売上 | 13.3% | 7.9% |
| 設備投資強度設備投資 / 売上 | 2.7% | 14.4% |
| キャッシュ転換率営業CF / 純利益 | 3.72× | 2.21× |
| 直近12ヶ月FCF直近4四半期 | $269.9M | $232.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $130.3M | $164.7M | ||
| Q3 25 | $118.5M | $205.2M | ||
| Q2 25 | $83.8M | $122.5M | ||
| Q1 25 | $7.4M | $98.2M | ||
| Q4 24 | $118.1M | $166.6M | ||
| Q3 24 | $141.8M | $218.1M | ||
| Q2 24 | $39.7M | $184.3M | ||
| Q1 24 | $-4.4M | $7.5M |
| Q4 25 | $108.5M | $58.5M | ||
| Q3 25 | $106.2M | $135.4M | ||
| Q2 25 | $61.0M | $53.0M | ||
| Q1 25 | $-5.8M | $-14.5M | ||
| Q4 24 | $102.9M | $76.0M | ||
| Q3 24 | $124.8M | $85.7M | ||
| Q2 24 | $29.0M | $78.8M | ||
| Q1 24 | $-13.6M | $-72.0M |
| Q4 25 | 13.3% | 7.9% | ||
| Q3 25 | 13.5% | 22.9% | ||
| Q2 25 | 8.4% | 8.0% | ||
| Q1 25 | -0.8% | -2.5% | ||
| Q4 24 | 14.1% | 11.7% | ||
| Q3 24 | 17.8% | 15.6% | ||
| Q2 24 | 4.1% | 12.9% | ||
| Q1 24 | -2.1% | -13.6% |
| Q4 25 | 2.7% | 14.4% | ||
| Q3 25 | 1.6% | 11.8% | ||
| Q2 25 | 3.2% | 10.5% | ||
| Q1 25 | 1.9% | 19.2% | ||
| Q4 24 | 2.1% | 14.0% | ||
| Q3 24 | 2.4% | 24.1% | ||
| Q2 24 | 1.5% | 17.2% | ||
| Q1 24 | 1.4% | 15.0% |
| Q4 25 | 3.72× | 2.21× | ||
| Q3 25 | 50.00× | 5.88× | ||
| Q2 25 | 3.74× | 1.71× | ||
| Q1 25 | 0.61× | 1.56× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 3.70× | ||
| Q2 24 | 6.62× | 1.83× | ||
| Q1 24 | — | 0.17× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RHP
| Hotel Other | $157.7M | 21% |
| Gaylord Opryland | $147.4M | 20% |
| Hotel Transient Rooms | $93.6M | 13% |
| Hotel Food And Beverage Outlets | $92.2M | 12% |
| Gaylord Palms | $88.2M | 12% |
| Jw Marriott Hill Country | $53.7M | 7% |
| Entertainment Admissions And Ticketing | $43.1M | 6% |
| Entertainment Food And Beverage | $38.1M | 5% |
| Entertainment Retail And Other | $28.3M | 4% |
| Ac Hotel | $2.4M | 0% |
